New Gene Therapy Offers Hope for Hemophilia B Patients

Karmanos Cancer Institute becomes first freestanding cancer center to offer cutting-edge treatment.

Apr. 17, 2026 at 11:18pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph of a human vein, glowing with a faint blue light, conceptually representing the fragile circulatory system and the promise of a new gene therapy treatment for Hemophilia B.A new gene therapy treatment offers hope for Hemophilia B patients, potentially restoring their body's ability to properly clot blood and reducing the need for lifelong medication.Today in Detroit

A new gene therapy treatment is bringing hope to patients with the rare genetic disorder Hemophilia B. The one-time infusion delivers a gene that helps blood clot properly, potentially eliminating the need for lifelong medication and offering a new lease on life for those affected. Karmanos Cancer Institute in Detroit is the first freestanding cancer center to offer this innovative therapy.

Why it matters

Hemophilia B is a life-threatening condition that has long required constant vigilance and treatment to manage bleeding episodes. This new gene therapy could be a game-changer, potentially freeing patients from the burden of daily medication and the risk of dangerous bleeding events.

The details

The gene therapy involves infusing a vector containing the gene for hemophilia factor IX directly into the patient's bloodstream. This one-time treatment aims to enable the body to produce the necessary clotting factor on its own, eliminating the need for regular prophylactic medication. Karmanos Cancer Institute is the first freestanding cancer center to offer this cutting-edge therapy, which has already been successful in 94% of patients who no longer require prophylaxis after the infusion.

  • Stephen Werner, a Hemophilia B patient, received the gene therapy infusion at the end of 2025.
  • Karmanos Cancer Institute began offering the new treatment in early 2026, becoming the first freestanding cancer center to do so.

The players

Stephen Werner

A 52-year-old Hemophilia B patient who received the new gene therapy treatment at Karmanos Cancer Institute, reporting a dramatic improvement in his condition and quality of life.

Dr. Indryas Woldie

A physician at Karmanos Cancer Institute who is overseeing the administration of the new gene therapy treatment for Hemophilia B patients.

Karmanos Cancer Institute

A leading cancer treatment and research center in Detroit, Michigan, that has become the first freestanding cancer center to offer the innovative gene therapy for Hemophilia B.

Got photos? Submit your photos here. ›

What they’re saying

“It's a one-time treatment where you deliver the gene for hemophilia factor IX.”

— Dr. Indryas Woldie, Physician, Karmanos Cancer Institute

“He's doing well after treatment. He's no longer using prophylaxis, and the five-year follow-up data from other patients shows 94% of patients don't have to use prophylaxis after this infusion.”

— Dr. Indryas Woldie, Physician, Karmanos Cancer Institute

“I feel fantastic. It's amazing, really, what it's done, and it's taking some concern away from me. I was in end-stage liver disease because of it, and now I'm perfectly healthy.”

— Stephen Werner, Hemophilia B Patient

What’s next

Karmanos Cancer Institute plans to continue offering the new gene therapy treatment for Hemophilia B patients, with the goal of expanding access to this innovative therapy across the state of Michigan.

The takeaway

This groundbreaking gene therapy treatment represents a major breakthrough for Hemophilia B patients, potentially freeing them from the lifelong burden of daily medication and the constant risk of dangerous bleeding episodes. Karmanos Cancer Institute's pioneering work in this field could pave the way for wider adoption of this transformative therapy, offering hope and a new lease on life for those affected by this rare and debilitating condition.